Connect with us


What’s happening with the CSL (ASX:CSL) share price?



Since listing in 1994, CSL Limited (ASX: CSL) has become a household name among Australian investors.  

The biotech giant has had a strong track record of performing consistently well, regardless of market conditions.

However, following an initial surge during the height of the COVID-19 pandemic, the CSL share price has struggled. This, despite the overall Australian share market enjoying a strong recovery.

How has CSL performed?

In mid-February, CSL reported a strong set of results for the 6 months ended 31 December. The company reported a 16.9% increase in revenue of US$5,739 million and 44% growth in net profit after tax (NPAT).

CSL noted that the COVID-19 pandemic had influenced the performance of its Behring and Seqirus…

Click here to view the original article.

Continue Reading

You might also like ...

Why retailers are stepping up as top performing ASX shares this week
Chimeric (ASX:CHM) share price finishes flat on quarterly update